BI-1701963 (Not yet branded)

Other Medications

US Experimental EU Experimental ES Not available Oral 4 Clinical Trials
Resistance pathway modulators (specific target not publicly disclosed)

Description

BI-1701963 is a targeted therapy designed to enhance the efficacy of KRAS G12C inhibitors in colorectal cancer patients. This compound is being developed by Boehringer Ingelheim as part of combination regimens, particularly with adagrasib (KRAS G12C inhibitor) and irinotecan chemotherapy. Based on clinical trial designs, BI-1701963 appears to target resistance mechanisms that limit the effectiveness of KRAS-targeted therapies in CRC patients harboring KRAS mutations.

Mechanism of Action

BI-1701963 likely functions by inhibiting specific resistance pathways that cancer cells activate to overcome KRAS G12C inhibition. The drug's mechanism appears designed to prevent adaptive responses that allow colorectal tumors to survive despite KRAS pathway blockade, thereby enhancing and prolonging the anti-tumor effects of KRAS inhibitors.

Molecular Targets

Side Effects

Fatigue Nausea Diarrhea Decreased appetite Abdominal pain Vomiting Constipation Headache

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04973163 Phase 1
Active, not recruiting
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
United States, Belgium, Spain, United Kingdom
NCT04975256 Phase 1
Archived
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
United States
NCT04627142 Phase 1
Archived
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
China
NCT04185883 Phase 1
Active, not recruiting
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
United States, Australia, Austria, Belgium, Canada, Germany, Italy, Japan, Nethe

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
EU EMA StatusExperimental
ES Spain AccessNot available
AdministrationOral
Clinical Trials4
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.